Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder.

CONTEXT Violent behavior of patients with schizophrenia prolongs hospital stay and interferes with their integration into the community. Finding appropriate treatment of violent behaviors is of primary importance. OBJECTIVE To compare the efficacy of 2 atypical antipsychotic agents, clozapine and olanzapine, with one another and with haloperidol in the treatment of physical assaults and other aggressive behaviors in physically assaultive patients with schizophrenia and schizoaffective disorder. DESIGN AND SETTING Randomized, double-blind, parallel-group, 12-week trial. Physically assaultive subjects with schizophrenia or schizoaffective disorder who were inpatients in state psychiatric facilities were randomly assigned to treatment with clozapine (n = 37), olanzapine (n = 37), or haloperidol (n = 36). MAIN OUTCOME MEASURES Number and severity of physical assaults as measured by the Modified Overt Aggression Scale (MOAS) physical aggression score and the number and severity of all aggressive events as measured by the MOAS overall score. Psychiatric symptoms were assessed through the Positive and Negative Syndrome Scale (PANSS). RESULTS Clozapine was superior to both olanzapine and haloperidol in reducing the number and severity of physical assaults as assessed by the MOAS physical aggression score and in reducing overall aggression as measured by the MOAS total score. Olanzapine was superior to haloperidol in reducing the number and severity of aggressive incidents on these 2 MOAS measures. There were no significant differences among the 3 medication groups in improvement of psychiatric symptoms as measured by the PANSS total score and the 3 PANSS subscales. CONCLUSIONS Clozapine shows greater efficacy than olanzapine and olanzapine greater efficacy than haloperidol in reducing aggressive behavior. This antiaggressive effect appears to be separate from the antipsychotic and sedative action of these medications.

[1]  Richard A. Van Dorn,et al.  Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. , 2004, The Journal of clinical psychiatry.

[2]  J. Lieberman,et al.  Overt Aggression and Psychotic Symptoms in Patients With Schizophrenia Treated With Clozapine, Olanzapine, Risperidone, or Haloperidol , 2004, Journal of clinical psychopharmacology.

[3]  June Corwin,et al.  Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. , 2003, JAMA.

[4]  P. Czobor,et al.  Characteristics of assaultive behavior among psychiatric inpatients. , 2003, Psychiatric services.

[5]  A. Green,et al.  Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone , 2003, Schizophrenia Research.

[6]  I. Glick,et al.  A meta-analysis of the efficacy of second-generation antipsychotics , 2003, Schizophrenia Research.

[7]  J. Lieberman,et al.  Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. , 2001, Psychiatric services.

[8]  Nancy H. Covell,et al.  Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. , 2000, Archives of general psychiatry.

[9]  J. Volavka,et al.  Atypical antipsychotics in the treatment of the persistently aggressive psychotic patient: methodological concerns , 1999, Schizophrenia Research.

[10]  W T Carpenter,et al.  Positive and negative symptom response to clozapine in schizophrenic patients with and without the deficit syndrome. , 1998, The American journal of psychiatry.

[11]  B J Burns,et al.  Violence and severe mental illness: the effects of substance abuse and nonadherence to medication. , 1998, The American journal of psychiatry.

[12]  J. Haller,et al.  Catecholaminergic involvement in the control of aggression: hormones, the peripheral sympathetic, and central noradrenergic systems , 1997, Neuroscience & Biobehavioral Reviews.

[13]  M. Angermeyer,et al.  The effect of violent attacks by schizophrenic persons on the attitude of the public towards the mentally ill. , 1996, Social science & medicine.

[14]  S. Schulz,et al.  Violence and schizophrenia: clozapine as a specific antiaggressive agent. , 1995, The Bulletin of the American Academy of Psychiatry and the Law.

[15]  P. Czobor,et al.  Effect of risperidone on hostility in schizophrenia. , 1995, Journal of clinical psychopharmacology.

[16]  R. Kerwin,et al.  Effect of Clozapine on d-Fenfluramine-Evoked Neuroendocrine Responses in Schizophrenia and its Relationship to Clinical Improvement , 1995, British Journal of Psychiatry.

[17]  P. Lelliott,et al.  A National Audit of New Long-Stay Psychiatric Patients , 1994, British Journal of Psychiatry.

[18]  J. Salamone,et al.  The effects of haloperidol and clozapine on PCP- and amphetamine-induced suppression of social behavior in the rat , 1994, Pharmacology Biochemistry and Behavior.

[19]  K. Miczek,et al.  Neurobiological mechanisms controlling aggression: Preclinical developments for pharmacotherapeutic interventions , 1994, Neuroscience & Biobehavioral Reviews.

[20]  J. Volavka,et al.  Clozapine effects on hostility and aggression in schizophrenia. , 1993, Journal of clinical psychopharmacology.

[21]  W. Wilson.  Clinical review of clozapine treatment in a state hospital , 1992, Schizophrenia Research.

[22]  P. Brain,et al.  Clozapine: Strong antiaggressive effects with minimal motor impairment , 1992, Physiology & Behavior.

[23]  H. Meltzer.  Role of serotonin in the action of atypical antipsychotic drugs. , 1990, Clinical neuroscience.

[24]  J. Swanson,et al.  Violence and psychiatric disorder in the community: evidence from the Epidemiologic Catchment Area surveys. , 1990, Hospital & community psychiatry.

[25]  D. Mcniel,et al.  Violent behavior and length of psychiatric hospitalization. , 1989, Hospital & community psychiatry.

[26]  Thomas A. Kent,et al.  Blood platelet uptake of serotonin in episodic aggression , 1989, Psychiatry Research.

[27]  S. Kay,et al.  Profiles of Aggression among Psychiatric Patients: I. Nature and Prevalence , 1988, The Journal of nervous and mental disease.

[28]  D. Cutler,et al.  Characteristics of state hospital patients who are hard to place. , 1988, Hospital & community psychiatry.

[29]  E. sanders-Bush,et al.  Adaptive changes in the 5-HT2 binding site after chronic administration of agonists and antagonists , 1986, Neuropharmacology.

[30]  B. Bunney,et al.  Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons , 1985, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[31]  J. Lieberman,et al.  Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs , 2005, Molecular Psychiatry.

[32]  C. Sánchez,et al.  The role of serotonergic mechanisms in inhibition of isolation-induced aggression in male mice , 2005, Psychopharmacology.

[33]  J. Csernansky,et al.  Subcortical dopamine and serotonin turnover during acute and subchronic administration of typical and atypical neuroleptics , 2005, Psychopharmacology.

[34]  M. Swartz,et al.  Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. , 2004, Schizophrenia bulletin.

[35]  R. Drake,et al.  The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. , 2000, Schizophrenia bulletin.

[36]  J. Monahan,et al.  Diagnostically Based Clues from the MacArthur Violence Risk Assessment Study , 2000 .

[37]  W. Wilson,et al.  18-month outcome of clozapine treatment for 100 patients in a state psychiatric hospital. , 1995, Psychiatric services.

[38]  J. Swanson.  Mental disorder, substance abuse, and community violence: An epidemiological approach. , 1994 .

[39]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.